-
Sector Analysis
Idiopathic Pulmonary Fibrosis (IPF) Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034
This report covers the 7 major markets and provides an Excel-based forecast model for the Idiopathic Pulmonary Fibrosis (IPF) market through 2034. GlobalData estimated that drug sales for IPF in 2024 were approximately $2.7 billion across the 7MM, with the market size anticipated to grow to approximately $5.8 billion by 2034, at a compound annual growth rate (CAGR) of 7.7%. Major drivers of growth during the forecast period include the launches of several pipeline agents, most notably Jascayd (nerandomilast), Tyvaso...
-
Sector Analysis
Idiopathic Pulmonary Fibrosis: Epidemiology Forecast to 2034
Idiopathic pulmonary fibrosis (IPF), a type of interstitial lung disease (ILD), is a serious chronic condition that affects the tissue surrounding the air sacs, or alveoli, in the lungs (National Heart Lung and Blood Institute, 2023). Environmental factors such as smoking, chronic aspiration, or respiratory infections, combined with advancing age, are the likely driving factors for the pathogenesis of IPF by causing respiratory alveolar epithelial injury (Sankari, Chapman and Ullah, 2024). These factors can cause permanent scarring in the lungs,...
-
Product Insights
Idiopathic Pulmonary Fibrosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Idiopathic Pulmonary Fibrosis - Global Clinical Trials Review, 2025" provides an overview of Idiopathic Pulmonary Fibrosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Idiopathic Pulmonary Fibrosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Sector Analysis
Idiopathic Pulmonary Fibrosis (IPF) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Idiopathic Pulmonary Fibrosis (IPF) Marketed and Pipeline Drugs Market Report Overview IPF is the most common subtype of idiopathic interstitial pneumonias (IIPs), which belong to a group of rare diseases termed interstitial lung diseases (ILDs). ILDs are characterized by damage to the lung parenchyma (the functional part of the lung that includes the alveolar tissue, bronchioles, bronchi, blood vessels, and interstitium) that occurs as a consequence of aberrant inflammation and fibrosis, thickening and scarring of the connective tissue. The development...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.